Please assess the completion status of the following clinical trial:

Trial Title: A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Subjects with HIV-1 infection.~* Are willing and able to understand and provide written consent prior to participation in this study.~Exclusion criteria:~* Are pregnant or breastfeeding.~* Have an active AIDS condition, pancreatitis, poor kidney function, or clinically relevant hepatitis.~* Have certain medical conditions that may make participation unsafe.~* Take medication that may interact with the study medication.~* Have a history of allergy to any of the study drugs or any excipients therein.~* Other inclusion/exclusion criteria to be evaluated by the physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FPV/r200 (Type: ACTIVE_COMPARATOR): Fosamprenavir/ritonavir (either 700/100mg BID or 1400/200mg QD)
- FPV/r100 (Type: EXPERIMENTAL): Fosamprenavir/ritonavir 1400/100mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).